Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDACs) and enhances the production of brain-derived neurotrophic factor (BDNF) in the CNS. Both mechanisms are relevant to the pathophysiology and treatment of major depression. We examined the antidepressant activity of fingolimod in mice subjected to chronic unpredictable stress (CUS), a model of reactive depression endowed with face and pharmacological validity. Chronic treatment with fingolimod (3 mg kg(-1), i.p., once a day for 4 weeks) reduced the immobility time in the forced swim test (FST) in a large proportion of CUS mice. This treatment also caused anxiogenic-like effects in the social interaction test without affecting anxiety-like behavior in the elevated plus maze or spatial learning in the water maze. CUS mice showed reduced BDNF levels and enhanced HDAC2 levels in the hippocampus. These changes were reversed by fingolimod exclusively in mice that showed a behavioral response to the drug in the FST. Fingolimod treatment also enhanced H3 histone K14-acetylation and adult neurogenesis in the hippocampus of CUS mice. Fingolimod did not affect most of the parameters we have tested in unstressed control mice. The antidepressant-like activity of fingolimod was confirmed in mice chronically treated with corticosterone. These findings show for the first time that fingolimod exerts antidepressant-like effect acting in a "disease-dependent" manner, and raise the interesting possibility that the drug could relieve depressive symptoms in MS patients independently of its disease-modifying effect on MS.

Antidepressant activity of fingolimod in mice / DI NUZZO, Luigi; Orlando, Rosamaria; Tognoli, C.; Di Pietro, P.; Bertini, G.; Miele, J.; Bucci, D.; Motolese, M.; Scaccianoce, Sergio; Caruso, Alessandra Sebastiana Maria; Mauro, G.; DE LUCIA, Carmine; Battaglia, G.; Bruno, Valeria Maria Gloria; Fabene, P.; Nicoletti, Ferdinando. - In: PHARMACOLOGY RESEARCH & PERSPECTIVES. - ISSN 2052-1707. - ELETTRONICO. - 3:3(2015), p. e00135. [10.1002/prp2.135]

Antidepressant activity of fingolimod in mice

DI NUZZO, LUIGI;ORLANDO, Rosamaria;SCACCIANOCE, Sergio;CARUSO, Alessandra Sebastiana Maria;DE LUCIA, CARMINE;G. Battaglia;BRUNO, Valeria Maria Gloria;NICOLETTI, Ferdinando
2015

Abstract

Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDACs) and enhances the production of brain-derived neurotrophic factor (BDNF) in the CNS. Both mechanisms are relevant to the pathophysiology and treatment of major depression. We examined the antidepressant activity of fingolimod in mice subjected to chronic unpredictable stress (CUS), a model of reactive depression endowed with face and pharmacological validity. Chronic treatment with fingolimod (3 mg kg(-1), i.p., once a day for 4 weeks) reduced the immobility time in the forced swim test (FST) in a large proportion of CUS mice. This treatment also caused anxiogenic-like effects in the social interaction test without affecting anxiety-like behavior in the elevated plus maze or spatial learning in the water maze. CUS mice showed reduced BDNF levels and enhanced HDAC2 levels in the hippocampus. These changes were reversed by fingolimod exclusively in mice that showed a behavioral response to the drug in the FST. Fingolimod treatment also enhanced H3 histone K14-acetylation and adult neurogenesis in the hippocampus of CUS mice. Fingolimod did not affect most of the parameters we have tested in unstressed control mice. The antidepressant-like activity of fingolimod was confirmed in mice chronically treated with corticosterone. These findings show for the first time that fingolimod exerts antidepressant-like effect acting in a "disease-dependent" manner, and raise the interesting possibility that the drug could relieve depressive symptoms in MS patients independently of its disease-modifying effect on MS.
2015
BDNF; chronic stress; depression; fingolimod; hippocampus
01 Pubblicazione su rivista::01a Articolo in rivista
Antidepressant activity of fingolimod in mice / DI NUZZO, Luigi; Orlando, Rosamaria; Tognoli, C.; Di Pietro, P.; Bertini, G.; Miele, J.; Bucci, D.; Motolese, M.; Scaccianoce, Sergio; Caruso, Alessandra Sebastiana Maria; Mauro, G.; DE LUCIA, Carmine; Battaglia, G.; Bruno, Valeria Maria Gloria; Fabene, P.; Nicoletti, Ferdinando. - In: PHARMACOLOGY RESEARCH & PERSPECTIVES. - ISSN 2052-1707. - ELETTRONICO. - 3:3(2015), p. e00135. [10.1002/prp2.135]
File allegati a questo prodotto
File Dimensione Formato  
Di-Nuzzo_Antidepressant_2015.pdf

accesso aperto

Note: Documento in post print
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.91 MB
Formato Adobe PDF
1.91 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/782195
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 33
social impact